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Abstract
Background: Systematic reviews of interventions provide a summary of the evidence available on intervention
effectiveness and harm. Cochrane systematic reviews (CSRs) have been published electronically in the Cochrane
Database of Systematic Reviews (CDSR) since 1994, and co-publication (publication of a Cochrane review in another
journal) has been allowed since that time, as long as the co-publishing journal has agreed to the arrangement.
Although standards for co-publication were established in 2008, the frequency of co-publication and adherence to
the standards have remained largely unexamined. Our objective was to examine the frequency of co-publication of
Cochrane Eyes and Vision Group (CEVG) reviews, adherence to the co-publication policy, the relative numbers of
citations of the two modes of publishing, and differences in times cited in CSRs with and without a co-publication.
Methods: We identified all CEVG reviews published by May 30, 2014 in The Cochrane Library. Using keywords from
the title, author names, and “Cochrane Eyes and Vision Group”, we searched Google Scholar, Web of Science,
Scopus, and PubMed databases to identify possible co-publications. We also emailed contact authors of all
identified CEVG reviews to ask them whether they had published their CSR elsewhere. We compared each co-
publication to the corresponding CEVG review for adherence to the Cochrane Policy Manual (dated June 10, 2014).
We recorded the number of times each CEVG review and each co-publication had been cited by others according
to Google Scholar, Web of Science, and Scopus, as of June 11, 2014.
Results: We identified 117 CEVG reviews;19 had been co-published in 22 articles. Adherence to Cochrane policy on
co-publication was moderate, with all authors complying with at least one of four requirements we addressed.
Co-publications were cited more often than the corresponding CEVG reviews; CEVG reviews with at least one
co-publication were cited approximately twice as often as CEVG reviews without a co-publication. The number of
citations varied considerably depending on whether the CEVG review had a co-publication or not.
Conclusions: The findings support encouraging co-publication while maintaining the primacy of the Cochrane
systematic review. Support for co-publication may be tempered by other factors such as the possibility that CEVG
reviews with a co-publication covered more clinically important and timely topics than those without a
co-publication. Assuming that citations are a valid measure of dissemination effectiveness, the 15-year CEVG
experience with co-publication of systematic reviews suggests that Cochrane authors should be encouraged to
co-publish in traditional medical journals.
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Background
Systematic reviews of interventions aim to provide a
summary of the evidence available to address a research
question about intervention effectiveness and harm.
Since 1994, Cochrane Systematic Reviews (CSRs) have
been published electronically in the Cochrane Database
of Systematic Reviews (CDSR), which is included in The
Cochrane Library, and they are updated as needed. To
attract authors and maximize dissemination of the re-
views, the Cochrane Collaboration encourages authors
to consider the option of “co-publishing” their CSRs in
traditional journals alongside their CDSR publication.
Both the Cochrane Editorial and Publishing Policy
Resource (referred to as the “Policy Manual” hereafter)
[1] and The Cochrane Handbook [2] have delineated co-
publication standards. The eight requirements for co-
publication are summarized in Additional file 1; only
four (one of which addresses two issues) can be exam-
ined for adherence in the text of a co-publication.
Whether to pursue co-publication in a traditional jour-
nal typically is the choice of CSR authors; in some cases,
co-publication may be suggested by Cochrane review
group editors when they deem the topic to be timely
and of special interest to clinicians and patients. For
example, the Cochrane Skin Group, which has co-
published about one third of their CSRs, encourages the
practice [3].
The objective of our cross-sectional study was to
examine the frequency of co-publication of Cochrane
Eyes and Vision Group (CEVG) reviews, adherence to
co-publication policy, whether co-publication of CSRs in
the field of eyes and vision has been associated with
additional citation of CSRs, and whether CSRs with co-
publications have been cited more often than CSRs
without co-publications. To our knowledge, these issues
have not been addressed for CSRs published by any
other Cochrane review group.
Methods
For Cochrane Collaboration-related projects, the Johns
Hopkins Bloomberg School of Public Health allows us to
query authors about their studies without specific ethics
approval. Otherwise, no humans were involved in this
research project, and we did not request ethics approval
for any portion of the project.
We selected for study all CEVG reviews published in
the CDSR as of May 30, 2014. We identified all poten-
tial co-publications using a three-step strategy. In the
first step, performed in January and February 2013, for
each CEVG review, we searched Web of Science and
Scopus citations for title words and the first author’s
surname. In the second step, we searched Google
Scholar and PubMed using the term “Cochrane eyes
and vision group”. In neither the first nor the second
step did we limit our searches by language of publica-
tion. In the third step, performed in March 2013, we
surveyed the contact authors of all CEVG reviews via
email to ask whether they had published elsewhere on
the topic of their CSR, specifically, whether they had
co-published a Cochrane review. When contact authors
appeared on more than one CSR, we asked about all re-
views on which their names appeared. We performed
final searches of the CDSR and citation databases on
June 11, 2014. We paired the most recent versions of
the CEVG reviews with co-publications, recognizing
that multiple CSRs can contribute to a single co-
publication and that one CSR may lead to two or more
co-publications on the same or different aspects of the
research question.
We used a pre-tested online data collection form, cre-
ated in Google Forms, to enter the study information for
each CEVG review-co-publication pair or group. The
online data collection form was pre-tested by collecting
data from several randomly selected co-publications and
corresponding CEVG reviews to ensure the complete-
ness of data collection. Data extracted include the
following: study characteristics such as journal of the co-
publication and Journal Impact Factor (JIF), comparison
of publication dates between co-publication and corre-
sponding CSR, authorship, number of included studies,
and fulfillment of each Policy Manual requirement for
the co-publication that we could evaluate. Details of data
extraction are provided in Additional file 2.
On June 11, 2014, we searched Google Scholar, Web
of Science, and Scopus for each review and each co-
publication and recorded the number of times each one
had been cited. Whenever multiple versions of a CEVG
review were found, we checked the citation list of each
co-publication to make sure that it cited no more than
one version of the same CSR. To obtain the total num-
ber of times each review was cited, we counted each
time a citation was made to any version of the review.
When two or more co-publications had emanated from
one CEVG review topic, we summed the times cited for
all co-publications. We also recorded the number of
times each co-publication and corresponding CEVG
review had been cited by the review authors themselves
(i.e., “self-citation”). We then compared the number of
citations for each co-publication and its corresponding
CEVG review, identified by the three citation resources,
using the Wilcoxon matched-pairs signed-rank test.
We compared the numbers of citations to CEVG re-
views with co-publications to the numbers of citations
of CEVG reviews without co-publications, using the
Wilcoxon rank-sum test, for each of the three citation
resources, including and excluding self-citations. All
statistical analyses were conducted using Stata 12
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(StataCorp. 2011. Stata Statistical Software: Release 12.
College Station, TX: StataCorp LP).
The Policy Manual requirements for co-publication of
CSRs are given in Additional file 1. Specifically, the jour-
nal version must faithfully reflect the Cochrane version,
indicate that it is a secondary publication, acknowledge
support from the CRG, and cite the Cochrane review.
We were able to evaluate adherence to four of the re-
quirements based on comparison of CSRs and corre-




As of May 30, 2014, 117 CEVG reviews had been pub-
lished in the CDSR. By searching citation and biblio-
graphic databases, we identified 21 co-publications
corresponding to 18 CEVG reviews. From our survey of
88 contact authors of 105 CEVG reviews published by
March 2013 to which 79 (90 %) of the contact authors
responded, we identified one co-publication from one
CSR not identified by our search. Therefore, we identified
a total of 22 co-publications corresponding to 19 CEVG
reviews. One co-publication [4] was generated from two
CEVG reviews [5, 6] and four CEVG reviews [7–10], each
had two co-publications [11–18]; there was one co-
publication from each of the remaining 13 CEVG reviews
[19–44]. Characteristics of the 22 co-publications are
summarized in Table 1.
Twelve of 22 (55 %) co-publications were in ophthal-
mology journals, and 10/22 (45 %) were published in gen-
eral medical or other journals (Table 1, Fig. 1). Among the
12 co-publications in seven ophthalmology journals, two
reviews were published in ophthalmology subspecialty
journals. Most CEVG co-publications (15/22; 86 %)
appeared in journals indexed in Google Scholar, Web of
Science, or Scopus at the time of publication. The median
JIF of the journals of co-publication was 1.83; the JIF
ranged from 0 (journals without JIFs) to 17.215 (BMJ).
Among the 12 journals, only one is open-access (Saudi
Medical Journal).
A majority of co-publications (63 %) were published
within 2 years after publication of the CEVG review.
However, five co-publications [17, 30, 40, 42, 44] were
published before the corresponding CEVG review. The
time difference between each CEVG review and co-
publication is shown in Fig. 2. A majority (62 %) of the
co-publications were based on the original (first) version
of the CEVG review.
Among the 18 co-publications with at least one in-
cluded study, 13 (72 %) cited all studies included in the
CEVG review, three (17 %) cited some of the included
studies [14, 26, 32], and two (11 %) did not cite any of
the included studies [16, 40].
Fulfillment of evaluable Policy Manual requirements for
co-publication
1. Reflect the data and interpretation of the CSR faithfully.
(Requirement 5, see Additional file 1)
Table 1 Characteristics of 22 co-publications matched to 19
Cochrane Eyes and Vision Group systematic reviews
Study characteristics N (%)
Co-publication content compared to the CEVG review
Identicala 3 (14 %)
Similar but not identicala 14 (64 %)
Abridgeda 3 (13 %)
Otherb 2 (9 %)
Journal of co-publication
Ophthalmology journal 12 (55 %)




General or other medical journal 10 (45 %)




Identical to CEVG review 11 (50 %)
Same authors, different order 3 (14 %)
One author added or removed 8 (36 %)
Co-publication timing
Before the CEVG reviewc 5 (23 %)
Within 2 years after CEVG review 14 (63 %)
More than 2 years after CEVG review 3 (14 %)
Co-publication based on
Original review 15 (68 %)
Updated review 7 (32 %)
Citation of the CEVG review by the co-publication
Cited 12 (55 %)
Not cited, but CEVG review mentioned in the text 4 (18 %)
Not cited or mentioned 6 (27 %)
Country of affiliation of co-publication first author
UK 16 (73 %)
USA 6 (27 %)
Number of included studies d
Same as CEVG review 16 (73 %)
Some overlap with CEVG review 6 (27 %)
aIdentical is exact copy of CSR, Similar would be applied, for example, when
the co-publication has a shorter methods section, and Abridged would be applied,
for example, when the co-publication is a summary of the major findings from CSR
bOf two co-publications classified as “Other”, one co-publication-CSR pair had
no included studies and the authors discussed the characteristics of the
condition; the second co-publication reported a subset of the interventions
described in the CEVG review
cFive CEVG reviews were published after the co-publications
dNumber of included studies in co-publication: 4 had 0 studies, 6 had 1–4
studies, 6 had 5–9 studies, and 6 had ≥10
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All 22 co-publications (100 %) had the same conclu-
sion (i.e., interpretation agreed) as the corresponding
CEVG review, although 6/22 (27 %) included a different
number of studies (i.e., data differed) from the CEVG
review (Additional file 3 lists the reasons).
2. Indicate that the journal version is a secondary
publication (complete republication, abridged republi-
cation, complete translation, or abridged translation).
(Requirement 6)
Thirteen of the 22 co-publications (59 %) indicated
that the co-publication was a secondary publication of
the CEVG review (see Additional file 4).
3. Acknowledge the support of the Cochrane Review
Group in publishing the CSR. (Requirement 7)
Half of the co-publications (11/22, 50 %) acknowledged
the support of the CEVG.
4. Cite the corresponding CSR in the co-publication
reference list and, when applicable (i.e., co-publication
Fig. 1 Journals of co-publication, by type of journal and Journal Impact Factor (JIF). Journal Impact Factor (JIF; rounded) as of March 9, 2015, is given
at the top of each bar
Fig. 2 Timing of publication of 18 pairs of CEVG reviews and corresponding co-publications. Note: green bars indicate co-publications published after
the CEVG review; red bars indicate co-publications published before the CEVG review
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was published before the most recent version of the
CSR), list the co-publication in the section “other pub-
lished versions of this review” of the corresponding CSR.
(Requirement 8)
Eleven of 22 (50 %) co-publications cited the corre-
sponding CEVG review; 6 of 19 (32 %) CEVG reviews
included the co-publication information in the “other
published versions of this review” section of the CSR
(Table 1).
Number of times cited
As shown in Table 2, the 22 co-publications had been
cited approximately 3.5 times as often as the correspond-
ing CEVG reviews, based on information in the Web of
Science and Scopus. Based on information from Google
Scholar, the number of citations to co-publications and
CEVG reviews were similar. Self-citations accounted for
fewer than 10 % of all citations and did not influence these
findings.
The 19 CEVG reviews with at least one co-publication
had been cited twice as often as the 98 CEVG reviews
without a co-publication, or more often when we consid-
ered the data retrieved from Google Scholar (Table 3).
Numbers of citations documented by Web of Science and
Google Scholar differed between co-published CEVG
reviews and CEVG reviews without co-publications but
were similar within Scopus (Table 3).
Discussion
Only a small proportion of CEVG reviews (19/117,
16.2 %) had been co-published based on information
available as of May 2014. The percentage of CSRs co-
published has changed little since 2007 (10/51; 19.6 %)
[45]. We do not know the reason for the relatively low
percentage; despite co-publication agreements with
many journals, many authors (and even editors) may
not be aware of them. Following a survey of authors
and editors in the field of dermatology, Cochrane au-
thors recommended that authors of CSRs who wish to
co-publish their reviews ‘minimize frustration’ by first
considering journals that have co-published other
Cochrane reviews [3].
Physicians and researchers who do not use or do not
have easy access to the CDSR may not be aware of im-
portant and up-to-date evidence synthesis it contains,
and co-publication could provide this access. Does co-
publication represent a form of duplicate publication?
We do not think so, as the Cochrane review is unlikely
to be “the same as” a co-publication, in that it is likely
to be much longer and its structure follows a specified
Cochrane format. Thus, one view could be that Cochrane
is helping to reduce research waste by its co-publication
policy, by making it more likely that the evidence gets to
clinicians and others who can use it. It would be worth
discussing whether Cochrane could do even more to re-
duce research waste by suggesting co-publication in open-
access journals.
For the same review topic, the co-publication had been
cited more often than the CEVG review, although the
difference was statistically significant only within the
Scopus database (Table 2). Although Web of Science and
Scopus produced lower citation estimates than Google
Scholar, nevertheless CEVG reviews with co-publications
also had been cited about twice as often as those reviews
without co-publications (Table 3).
The Policy Manual requirements for co-publication
typically had not been fulfilled by the authors of CEVG
reviews. All co-publications drew the same conclusions
about treatment effectiveness as the corresponding CEVG
reviews, including six that had different numbers of
included studies. However, when co-publications appeared
after or at the same time as the CEVG review (19/22 or
86 % of co-publications), only half of the co-publications
acknowledged the support of the CEVG or cited the
CEVG review. We recommend that the CEVG and other
Cochrane Review Groups who wish to encourage co-
publication monitor co-publications for fulfillment of the
Cochrane policy. Adherence to co-publication policies of
both Cochrane and individual journals should be import-
ant to editors of journals with co-publication agreements
with Cochrane [46].
Thus, co-publication, when the CSR is cited properly,
may bring attention to Cochrane reviews and increase
dissemination. Our findings support encouraging co-
publication while maintaining the primacy of the Cochrane
systematic review. Support for co-publication may be
tempered by other factors, of course, such as the reasons
for co-publication, a topic we have not explored in this
study. For example, it is possible that CEVG review authors
are more likely to pursue a co-publication for more clinic-
ally important and timely topics or for more complex
systematic reviews and meta-analyses. In addition, we do
not know whether any authors of CEVG reviews prepared
their findings for co-publication only to have their manu-
script rejected by editors who saw no need to use journal
space to publish information already publicly available.
As far as we know, the notion of co-publication, per se,
is unique to Cochrane systematic reviews. This is likely
because the Cochrane Collaboration has, from its begin-
ning in 1993, wanted to attract authors who sought
publishing outlets in addition to The Cochrane Library.
The Agency for Healthcare Research and Quality, another
commissioner of systematic reviews, publishes the Effect-
ive Healthcare Programs full reviews on its website
(http://www.ahrq.gov/research/findings/evidence-based-
reports/) and encourages authors to publish a shorter
version elsewhere as well (e.g., http://www.jclinepi.com/
content/jce-AHRQ-Series).
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Discussion within Cochrane as to whether authors
should be encouraged to co-publish in other journals
has mainly concerned broader dissemination and provid-
ing opportunities for attracting authors. For example, it
is possible that co-publications will be read and cited by
physicians and scientists and thus may lead readers to
consult the full Cochrane review; if this assumption is
correct, co-publication is one way to disseminate find-
ings of Cochrane reviews and to increase their influence.
On the other hand, co-publications may attract attention
to the co-publishing journal and may not draw attention
to Cochrane reviews; if this assumption is correct,
Cochrane reviews may be less cited and less influential
than the co-publications. Furthermore, if co-publications
are cited more often than Cochrane reviews, review
authors may be motivated to publish first in journals
other than The Cochrane Library. Some review groups
have asked whether it is a good idea to write to authors
of systematic reviews published elsewhere to convert
their reviews to CSRs. We found little evidence that this
strategy had been employed in the CEVG, since in only
3/22 cases of co-publication of CEVG reviews was there
evidence that the CSR was completed after the co-
publication [10, 39, 41].
We observed a tendency to increased citation of co-
publications over the CEVG reviews, regardless of the
database used to identify citations; however, the numbers
of citations identified by each source varied. Web of

















Barsam 2012 [20] 3 1 1 Barsam 2010 [19] 23 7 4
Buehl 2008 [22] 40 22 22 Findl 2007 [21] 100 43 37
Calderon 2011 [11] 32 20 21 Calderon 2011 [7] 19 7 1
Calderon 2012 [12] N/Aa N/Aa 0
Evans 2008 [4] 82 37 49 Evans 2006 [5] 111 45 14
Evans 2008 [6] 28 33 35
Fedorowicz 2006 [24] 12 8 6 Fedorowicz 2005 [23] 47 1 0
Gnanaraj 2005 [34] 12 3 9 Richardson 2003 [33] 32 4 12
Leyland 2003 [28] 183 109 130 Leyland 2001 [27] 87 26 18
Lueck 2002 [30] 11 N/Aa 8 Lueck 2002 [29] 77 0 10
Mabey 2003 [32] N/Aa N/Aa 5 Mabey 2002 [31] 69 6 9
Sheikh 2001 [13] 81 43 52 Sheikh 2000 [8] 158 33 21
Sheikh 2005 [14] 54 25 30
Shortt 2006 [36] 69 39 50 Shortt 2006 [35] 7 0 3
Shotton 2009 [15] N/Aa N/Aa N/Aa Shotton 2008 [9] 4 7 8
Shotton 2009 [16] N/Aa N/Aa N/Aa
Sivaprasad 2005 [38] 43 22 31 Sivaprasad 2005 [37] 83 2 8
Smeeth 1998 [40] 40 28 34 Smeeth 1998 [39] 44 7 4
Stanford 2003 [26] 79 36 48 Gilbert 2002 [25] 31 0 0
Wilhelmus 2000 [42] 42 N/Aa 28 Wilhelmus 2001 [41] 23 7 4
Wilkinson 1999 [17] 10 N/Aa 6 Wilkinson 2001 [10] 36 0 2
Wilkinson 2000 [18] 90 38 50
Wormald 2005 [44] N/Aa N/Aa N/Aa Wormald 2005 [43] 146 35 34
Median 42 26.5 28 40 7 8
Range 3 to 183 1 to 109 0 to 130 4 to 158 0 to 78 0 to 49
Wilcoxon matched-
pairs signed-rank testb
P = 0.32 P = 0.07 P = 0.004
All numbers cited include self-citations
aN/A indicates that the article was not found in Google Scholar, Web of Science or Scopus, sometimes because the journal was not indexed
bThe Wilcoxon matched-pairs signed-rank test was used to test the difference between the number of citations to each co-publication and its corresponding CEVG
review in each database (Google Scholar, Web of Science, and Scopus, respectively). We considered a value of P < 0.05 to indicate a statistically significant difference in
numbers of citations between a co-publication and its corresponding CEVG review
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Science had the smallest number of citations among the
three databases, and Google Scholar had the greatest
number of citations for both CEVG reviews and corre-
sponding co-publications. We noted that Google Scholar
took into account the numbers cited for multiple ver-
sions of CSRs and had not removed duplicate citations.
We expect that there are other differences between data-
bases that account for discrepancies in numbers of cita-
tions of both co-publications and CSRs, but we did not
seek to understand these discrepancies in any depth.
Although we imposed no language restrictions on our
search, we did not attempt to search any non-English
database. Given this fact, the lack of response from ten
contact authors to our inquiry and domination of Web
of Science, Scopus, Google Scholar, and PubMed by
English-language journals, it is possible that we missed
co-publications not in the English language. We also did
not survey review authors regarding their reasons for
co-publishing their CEVG review or choosing not to do
so.
The JIF, a ratio reflecting the number of citations to
articles published in a specific journal during the previ-
ous 2 years divided by the total number of citable arti-
cles published in the journal, is considered by many
publishers, readers, authors, and reviewers to be a
marker of a journal’s importance. The CDSR received its
first impact factor in 2007 (4.654) and its most recent
JIF in 2014 (6.032). This may not reflect the “impact” of
CEVG reviews however. To understand how the JIF and
other considerations have affected authors’ decisions to
co-publish or not, further surveys of review authors, both
those who have co-published and those who have not,
would be required. Editors also may be a factor in co-
publication. A 2008 survey of dermatology journal editors
found that most (6/11) editors who had co-published
Cochrane reviews believed that co-publication of the
review could increase their journal’s impact factor [3].
The Cochrane Back Review Group also recently exam-
ined co-publication and had similar findings to our own
[47]. With 62 published reviews, as of Issue 4, 2013 of The
Cochrane Library, and 59 co-publications (some Cochrane
reviews had more than one co-publication), a greater
proportion of their reviews had been co-published com-
pared to the CEVG reviews. For the ten most frequently
cited reviews from the Cochrane Back Review Group, the
number of citations to co-publications were generally the
same or greater than to the review itself; overall, the co-
publications had been cited about two times more often
than the ten top-cited Cochrane reviews.
Conclusions
Only about one in seven CEVG reviews have been co-
published, but, when they have been, co-publications
have been cited more often than the corresponding
CEVG reviews. If one accepts citations to be a valid
measure of dissemination effectiveness, the CEVG ex-
perience with co-publication of systematic reviews dur-
ing the past 15 years suggests that authors of CEVG
reviews who wish to increase dissemination of their
findings should co-publish them in traditional medical
journals. Cochrane review groups may be wise to invest
some resources in co-publication.
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